血府逐瘀胶囊对糖尿病肾病患者的辅助治疗效果  

Effect of Xuefu Zhuyu Capsule on adjuvant treatment of patients with diabetic nephropathy

作　　者：吴静南 徐鹏杰[2] WU Jing-nan;XU Peng-jie(Department of Traditional Chinese Medicine,Medical Community in Fenghua District Hospital of Traditional Chinese Medicine,Ningbo 315500,Zhejiang Province,China;Department of Nephrology,Ningbo Medical Center Lihuili Hospital,Ningbo 315040,Zhejiang Province,China)

机构地区：[1]宁波市奉化区中医医院医共体中医内科,浙江宁波315500 [2]宁波市医疗中心李惠利医院肾内科,浙江宁波315040

出　　处：《中国临床药理学杂志》2021年第18期2394-2396,2400,共4页The Chinese Journal of Clinical Pharmacology

摘　　要：目的观察血府逐瘀胶囊联合常规药物对病理分期Ⅲ期及以下的糖尿病肾病(DN)患者的辅助治疗效果与安全性。方法将78例患者依据随机数字表法分为对照组39例与试验组39例。对照组给予替米沙坦胶囊,每次80 mg,每日1次,口服;前列地尔注射液10μg+氯化钠注射液100 mL,每日1次,静脉滴注。试验组在对照组的基础上给予血府逐瘀胶囊,每次2.4 g,每日2次,口服。2组均治疗28 d。比较2组患者的尿蛋白、血清尿素氮(BUN)、肌酸酐(Scr)、超氧化物歧化酶(SOD)、丙二醛(MDA)水平及治疗效果和药物不良反应发生情况。结果治疗后,试验组和对照组的总有效率分别为100.00%和84.62%,差异有统计学意义(P<0.05)。治疗后,试验组和对照组的尿蛋白分别为(66.40±14.04)和(105.32±14.06)mg/24 h,BUN分别为(6.05±1.13)和(8.03±1.06)mmol·L^(-1),Scr分别为(78.11±9.68)和(84.01±7.90)μmol·L^(-1),SOD分别为(105.72±11.64)和(77.89±10.24)U·mL^(-1),MDA分别为(15.03±3.00)和(21.46±3.15)mmol·L^(-1),差异均有统计学意义(均P<0.05)。试验组和对照组的药物不良反应发生率分别为15.38%和20.51%,差异无统计学意义(P>0.05)。结论在临床分期在Ⅲ期及以下的DN患者人群中,使用血府逐瘀胶囊联合常规药物治疗,可改善肾功能指标、氧化应激水平,提升疗效,具有可靠的安全性。Objective To observe the adjuvant therapeutic effect and safety of Xuefu Zhuyu Capsules combined with conventional drugs in the treatment of patients with diabetic nephropathy(DN)with pathological stageⅢand below.Methods The 78 patients were divided into control group(39 cases)and treatment group(39 cases)according to the random number table method.Control group was given telmisartan capsules,80 mg each time,once a day,orally,alprostadil injection 10μg+NaCl injection 100 mL,once a day,intravenous drip.Treatment group was given Xuefu Zhuyu capsule,2.4 g each time,twice a day,orally on the basis of control group.Both groups were treated for 28 d.The levels of urinary protein,serum urea nitrogen(BUN),serum creatinine(Scr),superoxide dismutase(SOD),malondialdehyde(MDA)and clinical effect,incidence of adverse drug reactions were observed in two gorups.Results After treatment,the total effective rates of treatment group and control group were 100.00%and 84.62%,the difference was statistically significant(P<0.05).After treatment,the urine protein in treatment group and control group were(66.40±14.04)and(105.32±14.06)mg/24 h,BUN were(6.05±1.13)and(8.03±1.06)mmol·L^(-1),Scr were(78.11±9.68)and(84.01±7.90)μmol·L^(-1),SOD were(105.72±11.64)and(77.89±10.24)U·m L^(-1),MDA were(15.03±3.00)and(21.46±3.15)mmol·L^(-1),the difference was statistically significant(all P<0.05).The incidence of adverse drug reactions in treatment group and control group were 15.38%and 20.51%,the difference was not statistically significant(P>0.05).Conclusion In the clinical stage of DN patients with stageⅢand below,the use of Xuefu Zhuyu Capsules combined with conventional drug treatment can improve renal function indicators,inflammatory factors indicators and oxidative stress levels,enhance the efficacy,and have a reliable safety.

关 键 词：血府逐瘀胶囊 糖尿病肾病 肾功能 蛋白尿 氧化应激反应 

分 类 号：R28[医药卫生—中药学]